4592 Share Price Performance
JP¥0
-1667.00 (-100.00%)
Price JP¥0
Fair ValueJP¥2,100.00
Share Pricen/a
SanBio Company Limited Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
4592 Community Narratives
AN
Fair Value JP¥2.1k 7.8% undervalued intrinsic discount
Regenerative Medicine Tailwinds Will Support Long Term Brain Disease Treatment Potential
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value JP¥2.9k 33.2% undervalued intrinsic discount
Brain Regeneration Platform Will Transform Chronic Injury Treatment And Open Multiple Future Indications
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Regenerative Medicine Tailwinds Will Support Long Term Brain Disease Treatment Potential
Catalysts About SanBio SanBio is a regenerative medicine company focused on cell therapies for brain diseases such as traumatic brain injury. What are the underlying business or industry changes driving this perspective?Read more
24
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
JP¥2.1k
7.8% undervalued intrinsic discount
Fair Value
Profit Margin
24.59%
Future PE
29.78x
Price in 2029
JP¥0
Brain Regeneration Platform Will Transform Chronic Injury Treatment And Open Multiple Future Indications
Catalysts About SanBio SanBio is a regenerative medicine company focused on cell therapies for brain diseases such as traumatic brain injury and ischemic stroke. What are the underlying business or industry changes driving this perspective?Read more
4
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
JP¥2.9k
33.2% undervalued intrinsic discount
Fair Value
Profit Margin
7.86%
Future PE
589.96x
Price in 2029
JP¥0
Trending Discussion
Recently Updated Narratives
AN
Regenerative Medicine Tailwinds Will Support Long Term Brain Disease Treatment Potential
Fair Value: JP¥2.1k 7.8% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Brain Regeneration Platform Will Transform Chronic Injury Treatment And Open Multiple Future Indications
Fair Value: JP¥2.9k 33.2% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
SanBio Company Limited Key Details
About 4592
- Founded
- 2001
- Employees
- 29
- CEO
- WebsiteView website
SanBio Company Limited engages in the development, production, and sale of regenerative cell medicines for the central nervous system. It develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. The company’s research pipeline products also comprise SB623 for chronic cerebral infarction and chronic traumatic cerebral infarction injury, chronic cerebral hemorrhage, age-related macular degeneration, retinitis pigmentosa, spinal cord injury, Parkinson's disease, Alzheimer's disease, etc.; SB618 for peripheral neuropathy; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
